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 Th e roots and rhizomes of licorice ( Glycyr-
rhiza ) species have been used in both East-
ern and Western cultures since before  the 
Babylonian and Egyptian empires as sweet-
eners, mouth fresheners, and medical herb 
products for the treatment of dyspepsia, 
asthma, cough, and other conditions. 1 In 
modern times, licorice (Gan Cao) remains 
one of the most commonly prescribed 
herbs in Chinese traditional medicine. 1 
Th e active ingredient of licorice is glycyr-
rhizic acid, which is hydrolyzed into its 
aglycone, glycyrrhetinic acid (GA),  in vivo . 
Licorice products are made from peeled 
and unpeeled dried root, powdered or 
fi nely cut; these formulations have diff erent 
concentrations of glycyrrhizic acid that can 
vary from trace amounts to 20 % depend-
ing on of the extraction process. Carbenox-
olone, the hemisuccinate of GA, has been 
used successfully to treat patients with 
peptic ulceration. 2 Licorice possesses 
additional endocrine eff ects, including glu-
cocorticoid activity, antiandrogen eff ects, 
and estrogenic activity. 2,3 For the 
 nephrologist, the best known eff ect of lico-
rice is its ability to induce mineralocorti-
coid hypertension. 4 Patients consuming 
excessive quantities of licorice present with 
hypertension, hypokalemia, and metabolic 
alkalosis, 4 which may be severe enough to 
cause myopathy and cardiac arrhythmias. 
The condition is characterized by sup-
pressed plasma renin activity and aldoster-
one levels 5 and increased exchangeable 
Na   +   levels; it responds to spironolactone 
and is reversible upon the stopping of lico-
rice ingestion, 4,5 leading to the belief that 
licorice and licorice extract possess  ‘ deoxy-
cortone-like ’ eff ects. However, glycyrrhizic 
acid and GA have very low affi  nity for the 
mineralocorticoid receptor (MR) but 
are very potent competitive inhibitors 
of 11  -hydroxysteroid dehydrogenase 
type 2 (11  HSD2;  K i of approximately 
5 – 10  nmol), 4 and it is now clear that lico-
rice induces its mineralocorticoid eff ects 
through inhibition of 11  HSD2, the 
enzyme responsible for inactivating corti-
sol, rather than directly occupying and 
activating the MR. Th e MR is preferentially 
expressed in sodium-transporting epithelia 
such as the cortical collecting duct of the 
kidney and the epithelial cells of the colon. 6 
Although cortisol and aldosterone have the 
same affi  nity for MR, in these mineraloco-
rticoid target organs only aldosterone acts 
as the physiologic  agonist. Th e MR is pro-
tected from activation by glucocorticoids 
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 In patients on hemodialysis, Farese  et al. report that inhibition of the 
enzyme 11  -hydroxysteroid dehydrogenase type 2 by glycyrrhetinic 
acid, the active compound of licorice, reduces serum potassium 
concentration and the frequency of hyperkalemia, possibly by 
enhancing intestinal potassium loss. This finding could be an important 
tool to maintain predialysis [K   +   ] within safe limits in some dialysis 
patients at risk of hyperkalemic arrhythmias. 
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through the agency of the gatekeeper 
enzyme 11  HSD2, which converts bio-
logically active 11-hydroxysteroids to their 
inactive 11-keto-steroid forms, thus con-
ferring ligand specificity on the MR 
(Figure 1). Licorice administration to nor-
mal volunteers results in a mineralocorti-
coid excess state, an increase in the urinary 
(tetrahydrocortisol  +  5  tetrahydro-
cortisol) / tetrahydrocortisone, an increase 
in plasma cortisol half-life, and a decrease 
in circulating cortisone values, indicative 
of inhibition of 11  HSD2  in vivo . 5 
 Evidence of favorable therapeutic ben-
efi ts of licorice in humans has been lim-
ited. Some  in vivo and clinical studies have 
reported some benefi cial eff ects of both 
licorice and glycyrrhizin consumption, 
including antiulcer, antiviral, and hepato-
protective responses. 3 Farese  et al. 7 (this 
issue) propose a novel and potentially ben-
efi cial therapeutic eff ect of licorice and its 
active compound, GA, to persistently 
lower serum potassium concentration 
([K   +   ]) in patients with end-stage kidney 
disease. In a 6-month prospective, double-
blind, placebo-controlled crossover study, 
10 hemodialysis patients received cookies 
or bread rolls supplemented with either 
GA (500  mg / d) or placebo. Th e ratio of 
plasma cortisol to cortisone increased sig-
nifi cantly in all patients given GA as com-
pared with placebo, indicating signifi cant 
suppression of 11  HSD2 activity. 7 On GA, 
mean [K   +   ] was on average 1  mmol / l lower 
than on placebo, and the frequency of 
hyperkalemia (  6  mmol / l) was reduced 
from 9 % to 0.6 % . Th ese changes were not 
related to increased urinary potassium 
excretion in these patients, as residual 
renal clearance was less than 5  ml / min. 
Hence, the suggested mechanism underly-
ing the persistent reduction in [K   +   ] is 
colonic loss of potassium, most likely by 
activation of the MR by hydrocortisone as 
a consequence of the inhibition of 
11  HSD2 by GA. Although the authors 
did not measure fecal potassium excretion, 
this seems a plausible explanation, since in 
the rat colon, stimulation of the MR leads 
to net colonic sodium and water reabsorp-
tion, and potassium excretion. Th e authors 
conclude that the long-term  administration 
of GA-supplemented food persistently 
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described as inducing cardiac hypertrophy 
and fi brosis, 8 causing  infl ammatory and 
oxidative tissue responses, 9 and increasing 
infarct size aft er cerebral ischemia. 10 Th e 
average GA intake in the subjects of the 
Farese  et al. 7 study was around 6.8  mg / kg / d, 
which is higher than the estimated US con-
sumption of glycyrrhizin, 0.027 – 3.6  mg /
 kg / d, and the recommended acceptable 
daily intake. 3 On the other hand, signifi -
cant morbidity and mortality are associ-
ated with hyperkalemia-induced cardiac 
arrhythmias, and therefore the remarkable 
eff ects of GA on predialysis [K   +   ] observed 
by Farese and colleagues 7 in their end-stage 
kidney disease population may well off set 
the putative cardiovascular harm of GA. 
Future studies will need to determine 
whether inhibition of 11  HSD2 by licorice 
will reduce the incidence not only of hyper-
kalemia, but also of associated cardiac 
events in hemodialysis patients. 
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lowers [K   +   ] in dialysis patients without 
inducing weight gain or hypertension, thus 
providing an appealing treatment alterna-
tive to minimize the risk of hyperkalemia 
in end-stage kidney disease patients. 
 Hyperkalemia is a common problem in 
hemodialysis patients. Th ere are very few 
symptoms of hyperkalemia, and these tend 
to occur only at very high levels. Th e most 
dreaded and potentially life-threatening 
consequences of hyperkalemia are cardiac 
arrhythmias; the fi rst changes seen are a tall 
peaked T wave with shortened QT interval, 
and then progressive lengthening of the PR 
interval and QRS duration, and disappear-
ance of the P wave. Ventricular fi brillation or 
standstill is the most severe consequence. 
Although small amounts of potassium 
are lost each day in stool and sweat 
(10 – 15  mmol), the kidney plays the major 
role in the maintenance of potassium 
balance, appropriately varying potassium 
secretion with changes in dietary intake 
(normal range is 40 – 120  mmol / d). In end-
stage kidney disease patients, dietary potas-
sium intake leads to an increase in serum 
[K   +   ]. Clearly, adequacy of dialysis and 
dietary potassium restriction play an 
 important role in the prevention of hyperka-
lemia in this  population. However, in order 
to maintain predialysis [K   +   ] within safe lim-
its, some dialysis patients require regular 
intake of kayexalate, which can cause necro-
sis of the gastrointestinal tract. Th us, the 
option of licorice as an alternative agent to 
enhance gastrointestinal potassium removal 
as suggested by Farese  et al. 7 is enticing. 
 Should all dialysis patients, or at least 
those with recurrent hyperkalemia, enjoy 
a daily dose of cookies sweetened with 
licorice? Farese  et al. suggest that treatment 
with GA for up to 6 months is safe and 
eff ective with no evidence of signifi cant 
toxicity. 7 Nevertheless, some concerns 
should be raised with regard to theoreti-
cally harmful long-term side effects 
induced by overstimulation of the MR by 
glucocorticoids in nonepithelial tissues. In 
humans, 11   HSD2 enzyme is also 
expressed in the heart and vessels. Given 
that patients with end-stage kidney disease 
have a high cardiovascular burden, some 
questions may arise with regard to the 
long-term safety of MR overstimulation in 
other organs. In animal models, pharma-
cologic inhibition of 11  HSD2 has been 
 Figure 1  |  Enzyme dependence of mineralocorticoid target tissue specificity.  In 
mineralocorticoid target organs, aldosterone binds to the mineralocorticoid receptor (MR), and 
thereafter the ligand – receptor complex is translocated into the nucleus. Binding to its hormone 
response element (HRE) increases the transcription of genes encoding specific aldosterone-inducible 
proteins, such as the rate-limiting subunits of the apical epithelial sodium channel (ENaC), sgk-1 
and basolateral Na / K-ATPase. In turn, this stimulates sodium (Na   +   ) reabsorption and potassium 
(K   +   ) excretion.  In vitro , aldosterone and cortisol have similar affinity to the MR, yet only aldosterone 
acts as the physiologic MR agonist. The enzyme 11  -hydroxysteroid dehydrogenase type 2 
(11  HSD2) largely ( ~ 90 % ) converts cortisol to inactive cortisone, thereby protecting the MR from 
activation by cortisol. Inhibition of 11  HSD2 activity by glycyrrhetinic acid, the active compound 
of licorice, increases the intracellular cortisol level, leading to activation of the MR by cortisol. The 
resulting glucocorticoid activation of the MR produces the same effects as stimulation of the MR by 
aldosterone. NAD, nicotinamide adenine dinucleotide; NADH, reduced form of NAD. 
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